Bharat Parenterals is locked its upper circuit limit at Rs. 1516.20, up by 72.20 points or 5.00% from its previous closing of Rs. 1444.00 on the BSE.
The scrip opened at Rs. 1500.00 and has touched a high and low of Rs. 1516.20 and Rs. 1485.00 respectively. So far 5309 shares were traded on the counter.
The BSE group 'XT' stock of face value Rs. 10 has touched a 52 week high of Rs. 1824.70 on 30-Apr-2024 and a 52 week low of Rs. 361.00 on 26-Jun-2023.
Last one week high and low of the scrip stood at Rs. 1516.20 and Rs. 1350.60 respectively. The current market cap of the company is Rs. 989.24 crore.
The promoters holding in the company stood at 73.27%, while Institutions and Non-Institutions held 0.01% and 26.73% respectively.
Bharat Parenterals (BPL) has strategically acquired an additional 99,85,477 equity shares of Innoxel Lifesciences (Innoxel) at Rs 64.90 per share on preferential basis, by valuing the Innoxel for around Rs 648 crore. This led to increase in its stake of BPL from 51% to 55.89% in Innoxel.
Innoxel is an emerging CDMO specialising in aseptic production of Injectable vials, Pre-filled syringes and oral liquids. The first set of products from Innoxel has already commenced for exhibit batches and eventually will file with regulatory authorities. Innoxel has been designed, built, and now operated to enable it to be compliant with USFDA, EUGMP and MHRA norms.
Further, the board of BPL has proposed to acquire 2,50,000 equity shares (100% equity) of Varenyam Healthcare (VHPL) from current shareholders, enhancing its control and operational efficiency.
BPL has also proposed, subject to necessary approvals, acquisition of an additional 18,00,000 equity shares of Varenyam Biolifesciences (VBPL), valuing VBPL at around Rs 2.40 crore, raising BPL stake to 100%. The consideration for this acquisition involves a share swap, with BPL issuing 16,261 equity shares to VBPL shareholders as per the swap ratio identified by the Registered Valuer.
Bharat Parenterals is engaged in to the business of the Pharmaceuticals & Drugs.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: